Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia

Observational Program for Evaluation of Ribomustin Use in the First Line Therapy of Chronic Lymphocytic Leukemia

Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the first line therapy of chronic lymphocytic leukemia

Inclusion Criteria:

• Patients with chronic lymphocytic leukemia (CLL) with current or planned first line therapy with Ribomustin
• Informed Consent Form for personal data handling signed by the program participant

Exclusion Criteria:

• Any prior chemotherapy and/or radiotherapy and/or immunotherapy and/or any investigational agent for treatment of CLL
• Currently participating in any clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment
• Contraindications for Ribomustin usage in accordance with product label